211 related articles for article (PubMed ID: 38084667)
1. A patent perspective of antiangiogenic agents.
Zhang J; Wang J; Li Y; Pan X; Qu J; Zhang J
Expert Opin Ther Pat; 2023 Dec; 33(12):821-840. PubMed ID: 38084667
[TBL] [Abstract][Full Text] [Related]
2. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
3. An updated patent review of VEGFR-2 inhibitors (2017-present).
Farghaly TA; Al-Hasani WA; Abdulwahab HG
Expert Opin Ther Pat; 2021 Nov; 31(11):989-1007. PubMed ID: 34043477
[No Abstract] [Full Text] [Related]
4. Endogenous angiogenesis inhibitors as therapeutic agents: historical perspective and future direction.
Dhanabal M; Sethuraman N
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):223-36. PubMed ID: 18221039
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
6. Review of selected patents for cancer therapy targeting tumor angiogenesis.
Kirstein MN; Moore MM; Dudek AZ
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):153-61. PubMed ID: 18221033
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
[TBL] [Abstract][Full Text] [Related]
9. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
10. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Welti J; Loges S; Dimmeler S; Carmeliet P
J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.
Hoseinzadeh A; Ghoddusi Johari H; Anbardar MH; Tayebi L; Vafa E; Abbasi M; Vaez A; Golchin A; Amani AM; Jangjou A
Eur J Med Res; 2022 Nov; 27(1):232. PubMed ID: 36333816
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors in early development for gastric cancer.
Pinto MP; Owen GI; Retamal I; Garrido M
Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
[TBL] [Abstract][Full Text] [Related]
13. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
15. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.
Chimote G; Sreenivasan J; Pawar N; Subramanian J; Sivaramakrishnan H; Sharma S
Drug Des Devel Ther; 2014; 8():1107-23. PubMed ID: 25170251
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic application of anti-angiogenic nanomaterials in cancers.
Mukherjee S; Patra CR
Nanoscale; 2016 Jul; 8(25):12444-70. PubMed ID: 27067119
[TBL] [Abstract][Full Text] [Related]
19. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
20. [Expert consensus on off-label use of small molecule anti-angiogenic drugs in the treatment of metastatic breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):523-530. PubMed ID: 35754226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
